Lyell Immunopharma (LYEL) Operating Margin (2020 - 2025)
Lyell Immunopharma (LYEL) has disclosed Operating Margin for 6 consecutive years, with 2127400.0% as the latest value for Q4 2025.
- Quarterly Operating Margin fell 29879091.0% to 2127400.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 748344.44% through Dec 2025, down 16022149.0% year-over-year, with the annual reading at 748344.44% for FY2025, 16022149.0% down from the prior year.
- Operating Margin hit 2127400.0% in Q4 2025 for Lyell Immunopharma, down from 248353.33% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 30.55% in Q4 2022 to a low of 2214566.67% in Q3 2022.
- Historically, Operating Margin has averaged 564000.93% across 5 years, with a median of 240124.3% in 2023.
- Biggest five-year swings in Operating Margin: crashed -221278224bps in 2022 and later surged 197841067bps in 2023.
- Year by year, Operating Margin stood at 1684.55% in 2021, then skyrocketed by 98bps to 30.55% in 2022, then crashed by -1498065bps to 457753.85% in 2023, then crashed by -299bps to 1828609.09% in 2024, then dropped by -16bps to 2127400.0% in 2025.
- Business Quant data shows Operating Margin for LYEL at 2127400.0% in Q4 2025, 248353.33% in Q3 2025, and 589250.0% in Q2 2025.